Nasdaq · CIK 0001818844
DWTX Dogwood Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Mar 6, 2026.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
10
with a Form 4 at this company
Signals
Open-market buys and sells at Dogwood Therapeutics, Inc., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 29 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | Ralph Grosswald SVP OF OPERATIONS | AGrant or award Stock Option (right to buy)derivative | +82,500 | $0.00 | $0 | 82,500 | Mar 6, 2026 |
| Mar 5, 2026 | Roger Michael Gendreau CHIEF MEDICAL OFFICER | AGrant or award Stock Option (right to buy)derivative | +82,500 | $0.00 | $0 | 82,500 | Mar 6, 2026 |
| Mar 5, 2026 | Gregory Scott Duncan CHIEF EXECUTIVE OFFICER | AGrant or award Stock Option (right to buy)derivative | +330,000 | $0.00 | $0 | 330,000 | Mar 6, 2026 |
| Mar 5, 2026 | Angela Walsh Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +82,500 | $0.00 | $0 | 82,500 | Mar 6, 2026 |
| Dec 4, 2025 | Angela Walsh Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Dec 5, 2025 |
| Dec 4, 2025 | Ralph Grosswald SVP OF OPERATIONS | AGrant or award Stock Option (right to buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Dec 5, 2025 |
| Dec 4, 2025 | Roger Michael Gendreau CHIEF MEDICAL OFFICER | AGrant or award Stock Option (right to buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Dec 5, 2025 |
| Dec 4, 2025 | Gregory Scott Duncan CHIEF EXECUTIVE OFFICER | AGrant or award Stock Option (right to buy)derivative | +460,000 | $0.00 | $0 | 460,000 | Dec 5, 2025 |
| Nov 21, 2025 | Sealbond Ltd director, owner, other | CConversion Common Stock | +21,610,950 | - | - | 21,822,333 | Nov 25, 2025 |
| Nov 21, 2025 | Sealbond Ltd director, owner, other | CConversion Common Stockindirect: By Conjoint Inc. | +2,842,638 | - | - | 2,842,638 | Nov 25, 2025 |
| Nov 21, 2025 | Sealbond Ltd director, owner, other | CConversion Series A Preferred Stockderivative | -2,161 | $0.00 | $0 | 0 | Nov 25, 2025 |
| Nov 21, 2025 | Sealbond Ltd director, owner, other | CConversion Series A-1 Preferred Stockderivativeindirect: By Conjoint Inc. | -284 | $0.00 | $0 | 0 | Nov 25, 2025 |
| Jun 27, 2025 | David R Keefer director | AGrant or award Stock Option (right to buy)derivative | +2,362 | $0.00 | $0 | 2,362 | Jul 1, 2025 |
| Jun 27, 2025 | Roger Michael Gendreau CHIEF MEDICAL OFFICER | AGrant or award Stock Option (right to buy)derivative | +12,075 | $0.00 | $0 | 12,075 | Jul 1, 2025 |
| Jun 27, 2025 | Richard James Whitley director | AGrant or award Stock Option (right to buy)derivative | +2,362 | $0.00 | $0 | 2,362 | Jul 1, 2025 |
| Jun 27, 2025 | Ralph Grosswald SVP OF OPERATIONS | AGrant or award Stock Option (right to buy)derivative | +12,075 | $0.00 | $0 | 12,075 | Jul 1, 2025 |
| Jun 27, 2025 | John C Thomas director | AGrant or award Stock Option (right to buy)derivative | +2,362 | $0.00 | $0 | 2,362 | Jul 1, 2025 |
| Jun 27, 2025 | Gregory Scott Duncan CHIEF EXECUTIVE OFFICER | AGrant or award Stock Option (right to buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Jul 1, 2025 |
| Jun 27, 2025 | Angela Walsh Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +12,075 | $0.00 | $0 | 12,075 | Jul 1, 2025 |
| Jun 27, 2025 | Abel De La Rosa director | AGrant or award Stock Option (right to buy)derivative | +2,362 | $0.00 | $0 | 2,362 | Jul 1, 2025 |
| Jun 18, 2025 | Abel De La Rosa director | AGrant or award Stock Option (right to buy)derivative | +210 | $0.00 | $0 | 210 | Jun 23, 2025 |
| Jun 18, 2025 | John C Thomas director | AGrant or award Stock Option (right to buy)derivative | +210 | $0.00 | $0 | 210 | Jun 23, 2025 |
| Jun 18, 2025 | David R Keefer director | AGrant or award Stock Option (right to buy)derivative | +210 | $0.00 | $0 | 210 | Jun 23, 2025 |
| Jun 18, 2025 | Richard James Whitley director | AGrant or award Stock Option (right to buy)derivative | +210 | $0.00 | $0 | 210 | Jun 23, 2025 |
| Jun 18, 2025 | Abel De La Rosa director | AGrant or award Stock Option (right to buy)derivative | +210 | $0.00 | $0 | 420 | Jun 23, 2025 |
| Jun 18, 2025 | John C Thomas director | AGrant or award Stock Option (right to buy)derivative | +210 | $0.00 | $0 | 420 | Jun 23, 2025 |
| Jun 18, 2025 | David R Keefer director | AGrant or award Stock Option (right to buy)derivative | +210 | $0.00 | $0 | 420 | Jun 23, 2025 |
| Jun 18, 2025 | Richard James Whitley director | AGrant or award Stock Option (right to buy)derivative | +210 | $0.00 | $0 | 420 | Jun 23, 2025 |
| Mar 12, 2025 | CK Life Sciences Intl (Holdings) Inc director, owner, other | AGrant or award Series A-1 Preferred Stockderivativeindirect: See footnote | +284 | $7.01 | $1,993 | 284 | Mar 17, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- CK Life Sciences Intl (Holdings) Incdirector, owner, other
- Abel De La Rosadirector
- Gregory Scott DuncanCHIEF EXECUTIVE OFFICER
- Roger Michael GendreauCHIEF MEDICAL OFFICER
- Ralph GrosswaldSVP OF OPERATIONS
- David R Keeferdirector
- Sealbond Ltddirector, owner, other
- John C Thomasdirector
- Angela WalshChief Financial Officer
- Richard James Whitleydirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.